AU2018233976B2 - Fc-optimized anti-CD25 for tumour specific cell depletion - Google Patents

Fc-optimized anti-CD25 for tumour specific cell depletion Download PDF

Info

Publication number
AU2018233976B2
AU2018233976B2 AU2018233976A AU2018233976A AU2018233976B2 AU 2018233976 B2 AU2018233976 B2 AU 2018233976B2 AU 2018233976 A AU2018233976 A AU 2018233976A AU 2018233976 A AU2018233976 A AU 2018233976A AU 2018233976 B2 AU2018233976 B2 AU 2018233976B2
Authority
AU
Australia
Prior art keywords
antibody
seq
cells
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018233976A
Other languages
English (en)
Other versions
AU2018233976A1 (en
Inventor
Frederick ARCE VARGAS
Anne Goubier
Beatriz GOYENECHEA CORZO
Pascal Merchiers
Kevin Moulder
Karl PEGGS
Sergio Quezada
Josephine SALIMU
Isabelle SOLOMON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Tusk Therapeutics Ltd
Original Assignee
Cancer Research Technology Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018233976(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1710879.6A external-priority patent/GB201710879D0/en
Priority claimed from GBGB1714429.6A external-priority patent/GB201714429D0/en
Application filed by Cancer Research Technology Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2018233976A1 publication Critical patent/AU2018233976A1/en
Application granted granted Critical
Publication of AU2018233976B2 publication Critical patent/AU2018233976B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018233976A 2017-03-17 2018-03-13 Fc-optimized anti-CD25 for tumour specific cell depletion Active AU2018233976B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17161717.8 2017-03-17
EP17161717 2017-03-17
GB1710879.6 2017-07-06
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion
GBGB1714429.6A GB201714429D0 (en) 2017-09-07 2017-09-07 Compounds and methods for tumour-specific cell depletion
GB1714429.6 2017-09-07
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion

Publications (2)

Publication Number Publication Date
AU2018233976A1 AU2018233976A1 (en) 2019-10-31
AU2018233976B2 true AU2018233976B2 (en) 2025-03-20

Family

ID=61655786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018233976A Active AU2018233976B2 (en) 2017-03-17 2018-03-13 Fc-optimized anti-CD25 for tumour specific cell depletion

Country Status (26)

Country Link
US (1) US11879014B2 (enExample)
EP (1) EP3596123B1 (enExample)
JP (2) JP2020514363A (enExample)
KR (1) KR20190130137A (enExample)
CN (1) CN110869388B (enExample)
AU (1) AU2018233976B2 (enExample)
BR (1) BR112019017017A2 (enExample)
CA (1) CA3056506A1 (enExample)
CL (1) CL2019002624A1 (enExample)
CR (1) CR20190477A (enExample)
DK (1) DK3596123T3 (enExample)
ES (1) ES2975063T3 (enExample)
FI (1) FI3596123T3 (enExample)
HR (1) HRP20240469T1 (enExample)
HU (1) HUE065999T2 (enExample)
IL (1) IL269081A (enExample)
LT (1) LT3596123T (enExample)
MX (1) MX2019010974A (enExample)
MY (1) MY208220A (enExample)
NZ (1) NZ756984A (enExample)
PE (1) PE20191812A1 (enExample)
PL (1) PL3596123T3 (enExample)
RS (1) RS65351B1 (enExample)
SG (1) SG11201908578YA (enExample)
SI (1) SI3596123T1 (enExample)
WO (1) WO2018167104A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019175224A1 (en) * 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
WO2020102591A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
WO2020102603A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Engineered cd25 polypeptides and uses thereof
JP2022538733A (ja) * 2019-05-20 2022-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 新規抗ｃｄ２５抗体
JP7245358B2 (ja) * 2019-06-10 2023-03-23 山東博安生物技術股▲ふん▼有限公司 抗ｃｄ２５抗体及びその適用
CA3179937A1 (en) 2020-04-10 2021-10-14 Rakuten Medical, Inc. Phthalocyanine dye compounds, conjugates and methods of use thereof
WO2021228218A1 (zh) * 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
US20240002521A1 (en) * 2020-11-20 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
AU2021380966A1 (en) * 2020-11-20 2023-06-22 Alderaan Biotechnology Anti-cd25 antibodies
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
JP2024505556A (ja) * 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法
BR112023017638A2 (pt) 2021-03-01 2023-10-10 Hoffmann La Roche Biomarcador, métodos para identificar um paciente com câncer e para tratar um paciente que sofre de câncer e agente anti-cd25
US20240352136A1 (en) 2021-09-02 2024-10-24 Hoffmann-La Roche Inc. Antibodies for the treatment of aml
EP4514388A1 (en) 2022-04-26 2025-03-05 F. Hoffmann-La Roche AG Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
AU2023299296A1 (en) * 2022-06-30 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof
CN119451978A (zh) 2022-07-01 2025-02-14 神经基因治疗公司 Neo-2/15变体及其用于优先刺激T调节细胞的用途
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN118240080A (zh) * 2022-12-22 2024-06-25 深圳市福元生物科技有限公司 一种cd25单域抗体、人源化抗体、及制备方法
WO2024165454A1 (en) 2023-02-06 2024-08-15 F. Hoffmann-La Roche Ag Combination therapy and uses thereof
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒
CN120314588B (zh) * 2025-05-21 2025-10-17 成都蓉生药业有限责任公司 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO2004045512A2 (en) 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP2038417A2 (en) 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
CA2932012A1 (en) 2006-08-18 2008-02-21 Novartis Ag Prlr-specific antibody and uses thereof
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
EA026336B1 (ru) 2009-09-22 2017-03-31 Пробиоген Аг Клетка позвоночного или насекомого для продукции белка или липида, не содержащего фукозу или содержащего сниженное количество фукозы, и ее применения
EP3336102A3 (en) * 2009-12-21 2018-08-01 Regeneron Pharmaceuticals, Inc. Humanized fc gamma r mice
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
CN106432495A (zh) 2010-07-22 2017-02-22 加利福尼亚大学董事会 抗肿瘤抗原抗体及其使用方法
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2014145000A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
EP2970489A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7325959B2 (ja) 2016-04-07 2023-08-15 キャンサー・リサーチ・テクノロジー・リミテッド 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
MX2020008769A (es) 2018-03-13 2020-10-08 Tusk Therapeutics Ltd Agentes anticuerpos anti-cd25.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PHILLIPS ET AL: 2000 IL-2Ralpha-directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2Ralpha Interaction, CANCER RESEARCH, vol. 60, p. 6977 - 6984 *
Poirier, M. et al. 2009 A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma, Journal of Oncology, vol. 2009, Art. ID 963037, 8 pages. https://doi.org/10.1155/2009/963037 *
SAMPSON ET AL: 2012 A Pilot Study of IL-2R[alpha] Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma, PLOS ONE, vol. 7, no. 2, pages e31046 *
Zhang, M. et al. 2004 "Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia", CANCER RESEARCH 64, 5825-5829 *

Also Published As

Publication number Publication date
US20200010554A1 (en) 2020-01-09
IL269081A (en) 2019-11-28
KR20190130137A (ko) 2019-11-21
JP2024050684A (ja) 2024-04-10
HRP20240469T1 (hr) 2024-07-19
HUE065999T2 (hu) 2024-06-28
BR112019017017A2 (pt) 2020-04-14
RS65351B1 (sr) 2024-04-30
SI3596123T1 (sl) 2024-05-31
FI3596123T3 (fi) 2024-04-17
CL2019002624A1 (es) 2020-04-03
CN110869388B (zh) 2024-09-20
CA3056506A1 (en) 2018-09-20
LT3596123T (lt) 2024-03-25
CR20190477A (es) 2020-01-07
SG11201908578YA (en) 2019-10-30
NZ756984A (en) 2025-08-29
PL3596123T3 (pl) 2024-06-24
MX2019010974A (es) 2020-08-03
WO2018167104A1 (en) 2018-09-20
EP3596123A1 (en) 2020-01-22
ES2975063T3 (es) 2024-07-03
MY208220A (en) 2025-04-24
US11879014B2 (en) 2024-01-23
PE20191812A1 (es) 2019-12-26
EP3596123B1 (en) 2024-01-10
JP2020514363A (ja) 2020-05-21
DK3596123T3 (da) 2024-02-26
AU2018233976A1 (en) 2019-10-31
CN110869388A (zh) 2020-03-06

Similar Documents

Publication Publication Date Title
AU2018233976B2 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
US11851494B2 (en) Anti-CD25 for tumour specific cell depletion
JP7225135B2 (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
WO2022003156A1 (en) Ccr8 non-blocking binders
EP4267618A1 (en) Non-blocking human ccr8 binders
WO2022136647A1 (en) Human ccr8 binders
EP4267621A1 (en) Murine cross-reactive human ccr8 binders
EP4255929A2 (en) An ltbr agonist in combination therapy against cancer
RU2839380C1 (ru) Fc-оптимизированные антитела к cd25 для истощения опухолеспецифических клеток
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion
HK40016585B (zh) 用於肿瘤特异性细胞消耗的fc优化的抗cd25
HK40018012A (en) Compounds and methods for tumour-specific cell depletion

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)